111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Drug Mall, including pharmacies and wholesalers; and digital contract sales organization and data services. As of December 31, 2020, it operated 13 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Wuhan, Tianjin, and Kunshan. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. 111, Inc. has strategic partnerships with Bayer Healthcare Co. Ltd.; BeiGene, Ltd.; and Jianming Pharmaceutical Group. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
IPO Year: 2018
Exchange: NASDAQ
Website: 111.com.cn
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup resumed coverage of 111, Inc. with a rating of Buy and set a new price target of $16.00
Fastest customizable press release news feed in the world
Transition from An Asset-Heavy Business Model to An Asset-Light Business ModelAchieved Quarterly Non-GAAP Net ProfitabilityMaintained Non-GAAP Operational Profitability for Three Consecutive QuartersAchieved Quarterly Positive Operating Cash FlowSHANGHAI, Dec. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total operating expenses were RMB180.3 million (US$25.3 million)
Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoYMaintained Positive Operating Cash Flow in the First Half of the YearSHANGHAI, Sept. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Total operating expenses were RMB185.3 million (US$25.9 million), an improvement of 9.3% compared to RMB204.3 million in
Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoYMaintained Quarterly Positive Operating Cash FlowSHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net revenues were RMB3.5 billion (US$486.3 million), remaining relatively flat compared to the same quarter last year.Total operating expenses
Achieved First-Ever Annual Operating ProfitBottom Line Improved by RMB332.7 Million YoY in 2024Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoYAchieved First-Ever Annual Positive Operating Cash FlowSHANGHAI, March 20, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Four
SHANGHAI, March 12, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research ("WTR") on Wednesday, March 26, 2025 at 11:00 a.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's Q4 2024 earnings (to be reported on Thursday, March 20, 2024), its priorities and goals for 2025, and an updated overview of the macroenvironment. To
SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2024 ended December 31, 2024, before the U.S. market opens on Thursday, March 20, 2025. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 20, 2025 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Fourth Q
SHANGHAI, Feb. 11, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced today that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") on February 10, 2025, confirming that Nasdaq has determined that for the last ten consecutive business days, from January 24, 2025 to February 7, 2025, the closing bid price of the Company's American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1). Nasda
SHANGHAI, Jan. 8, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to Class A ordinary shares from one (1) ADS representing two (2) Class A ordinary shares to the new ratio of one (1) ADS representing twenty (20) Class A ordinary shares. For the Company's ADS holders, this ratio change will have the same effect as a one-for-ten reverse ADS split. There will be no change to 111's underlying Class A ordinary s
Maintained Operational Profitability for the Third Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoYHeld Positive Operating Cash Flow for Three Consecutive QuartersSHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same
SHANGHAI, Nov. 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research ("WTR") on Friday, December 6, 2024 at 11:00 a.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's Q3 2024 earnings (to be reported on Wednesday, November 27, 2024), along with challenges, opportunities, and the NASDAQ share price compliance issue. T
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
20-F/A - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
20-F - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
Live finance-specific insights
Achieved First-Ever Annual Operating ProfitBottom Line Improved by RMB332.7 Million YoY in 2024Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoYAchieved First-Ever Annual Positive Operating Cash FlowSHANGHAI, March 20, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Four
SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2024 ended December 31, 2024, before the U.S. market opens on Thursday, March 20, 2025. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 20, 2025 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Fourth Q
Maintained Operational Profitability for the Third Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoYHeld Positive Operating Cash Flow for Three Consecutive QuartersSHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that its release of unaudited financial results for the third quarter ended September 30, 2024, previously scheduled for Thursday, November 28, 2024, will now occur before the U.S. market opens on Wednesday, November 27, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Wednesday, November 27, 2024 (8:30 PM Beijing Time on the same day). Details for the conference call a
SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2024, before the U.S. market opens on Thursday, November 28, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, November 28, 2024 (8:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Third Quarter 2024 Earn
Maintained Operational Profitability for the Second Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoYHeld Positive Operating Cash Flow for Two Consecutive QuartersSHANGHAI, Aug. 29, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Net revenues were RMB3.4 billion (US$471.2 million) and gross segment profit (1) was RMB 207.6 million
SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2024, before the U.S. market opens on Thursday, August 29, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 29, 2024 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Second Quarter 2024 Earnings Co
Turned to Quarterly Operational Profitability for the First TimeOperating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8%Achieved Positive Operating Cash FlowSHANGHAI, May 23, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Net revenues were RMB3.5 billion (US$488.7 million) and Gross segment profit (1) was RMB 208.5 million (US$ 28.9 million). Due to
SHANGHAI, April 30, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024, before the U.S. market opens on Thursday, May 23, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, May 23, 2024 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. First Quarter 2024 Earnings Conference CallRegistration Link: https:/
SHANGHAI, March 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Highlights Net revenues were RMB4.1 billion (US$578.7 million), representing a decrease of 1.0% year-over-year.Gross segment profit (1) was RMB 214.3 million (US$ 30.2 million), decreased by 15.5% year-over-year.Total operating expenses were RMB420.8 million (US$59.3 million), compared to RMB361.9 million in the same quarter of last y
Live Leadership Updates
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024. Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr
SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced the appointment of Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar
SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors (the "Board") has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding proposal letter dated September 9, 2022 (the "Proposal")
This live feed shows all institutional transactions in real time.
SC 13D/A - 111, Inc. (0001738906) (Subject)
SC 13D/A - 111, Inc. (0001738906) (Subject)
SC 13D/A - 111, Inc. (0001738906) (Subject)
SC 13D - 111, Inc. (0001738906) (Subject)
SC 13G/A - 111, Inc. (0001738906) (Subject)
SC 13G/A - 111, Inc. (0001738906) (Subject)
SC 13G/A - 111, Inc. (0001738906) (Subject)